Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
NCT06935591 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).
Conditions Studied
Interventions
- PROCEDURE Pulmonary Vein Isolation
- DEVICE vMap® + Pulmonary Vein Isolation
Study Locations (13)
Florida
- BayCare Health System — Clearwater
- Baptist Health Jacksonville — Jacksonville
- USF Health — Tampa
Georgia
- Piedmont Heart of Athens — Athens
- Piedmont Heart Institute — Atlanta
Ohio
- OhioHealth — Columbus
- University of Toledo Medical Center — Toledo
Arkansas
- Arrhythmia Research Group - St. Bernards — Jonesboro
Indiana
- Indiana University — Indianapolis
Kentucky
- Baptist Health Lexignton — Lexington
New York
- Westchester Medical Center — Valhalla
Pennsylvania
- Penn Presbyterian — Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06935591
The ClinicalTrials.gov registry entry for NCT06935591 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vektor Medical, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 2 interventions — of which Pulmonary Vein Isolation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06935591 reports 13 study locations spanning 9 distinct geographic areas — top geographies include Florida, Georgia, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06935591 about?
NCT06935591 is a clinical study titled "Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study". The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or ...
What is the current status of trial NCT06935591?
This trial is currently recruiting. It is a NA study. The enrollment target is 423 participants. The study started on 2025-06-27. Estimated completion is 2027-12.
What conditions does trial NCT06935591 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06935591?
The interventions under investigation include: Pulmonary Vein Isolation (PROCEDURE), vMap® + Pulmonary Vein Isolation (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06935591?
This trial is sponsored by Vektor Medical, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06935591 being conducted?
This trial has 13 study locations across Arkansas, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.